Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST StudyJ.F.R. Robertson, Matthew J. Ellis, Antonio Llombart‐Cussac et al.|Journal of Clinical Oncology|2009Cited by 312
Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST StudyMatthew J. Ellis, J.F.R. Robertson, Yuri Rukazenkov et al.|Journal of Clinical Oncology|2015Cited by 239
Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ studyJ.F.R. Robertson, Matthew J. Ellis, John Dewar et al.|Breast Cancer Research and Treatment|2012Cited by 172